Nifty
Sensex
:
:
11274.20
38014.62
569.40 (5.32%)
1921.15 (5.32%)

Pharmaceuticals & Drugs

Rating :
47/99

BSE: 532531 | NSE: STAR

360.10
20-Sep-2019
  • Open
  • High
  • Low
  • Previous Close
  •  362.50
  •  373.50
  •  356.80
  •  359.55
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  1166038
  •  4244.07
  •  551.40
  •  337.55

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 3,223.78
  • 9.69
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 5,928.60
  • 0.83%
  • 1.20

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 31.24%
  • 0.00%
  • 12.01%
  • FII
  • DII
  • Others
  • 3.89%
  • 19.71%
  • 33.15%

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 20.29
  • -7.67

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 14.48
  • -2.73

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 198.64
  • -2.26

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.05
  • 22.56
  • 20.92

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.07
  • 3.48
  • 2.36

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.56
  • 19.12
  • 14.60

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Net Sales
685.80
663.46
3.37%
839.70
669.89
25.35%
794.50
748.79
6.10%
732.63
768.66
-4.69%
Expenses
564.88
582.68
-3.05%
680.97
577.63
17.89%
667.41
617.83
8.02%
633.03
660.88
-4.21%
EBITDA
120.92
80.78
49.69%
158.73
92.26
72.05%
127.09
130.96
-2.96%
99.60
107.78
-7.59%
EBIDTM
17.63%
12.18%
18.90%
13.77%
16.00%
17.49%
13.59%
14.02%
Other Income
10.25
10.64
-3.67%
14.78
16.06
-7.97%
0.83
15.66
-94.70%
7.73
22.14
-65.09%
Interest
35.34
44.12
-19.90%
62.65
45.47
37.78%
50.09
49.77
0.64%
48.48
48.58
-0.21%
Depreciation
42.89
42.87
0.05%
43.82
44.34
-1.17%
40.67
37.95
7.17%
44.49
37.25
19.44%
PBT
46.29
-0.51
-
76.01
-3.14
-
37.90
52.58
-27.92%
6.97
31.84
-78.11%
Tax
3.12
-4.27
-
11.05
-4.96
-
6.33
2.01
214.93%
1.61
5.42
-70.30%
PAT
43.17
3.76
1,048.14%
64.96
1.82
3,469.23%
31.57
50.57
-37.57%
5.36
26.42
-79.71%
PATM
6.29%
0.57%
7.74%
0.27%
3.97%
6.75%
0.73%
3.44%
EPS
0.41
-0.66
-
5.31
63.65
-91.66%
32.77
9.56
242.78%
-1.34
0.96
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Net Sales
3,052.63
3,011.68
3,338.63
3,826.22
2,862.19
1,195.85
1,340.96
961.76
2,550.04
1,695.84
1,304.77
Net Sales Growth
7.08%
-9.79%
-12.74%
33.68%
139.34%
-10.82%
39.43%
-62.28%
50.37%
29.97%
 
Cost Of Goods Sold
1,441.42
1,466.00
1,378.84
1,281.17
1,502.29
560.49
714.67
491.82
1,264.39
805.65
700.90
Gross Profit
1,611.21
1,545.67
1,959.80
2,545.05
1,359.90
635.37
626.30
469.94
1,285.66
890.19
603.86
GP Margin
52.78%
51.32%
58.70%
66.52%
47.51%
53.13%
46.71%
48.86%
50.42%
52.49%
46.28%
Total Expenditure
2,546.29
2,561.63
2,987.89
3,309.30
2,481.62
967.00
1,117.54
861.18
2,059.36
1,369.22
1,117.84
Power & Fuel Cost
-
54.67
51.33
33.87
77.18
16.02
18.56
12.84
54.24
30.23
24.58
% Of Sales
-
1.82%
1.54%
0.89%
2.70%
1.34%
1.38%
1.34%
2.13%
1.78%
1.88%
Employee Cost
-
442.58
434.05
419.16
357.69
172.06
157.18
120.30
302.74
219.57
177.01
% Of Sales
-
14.70%
13.00%
10.95%
12.50%
14.39%
11.72%
12.51%
11.87%
12.95%
13.57%
Manufacturing Exp.
-
119.16
115.97
137.47
119.23
41.37
35.76
44.43
89.60
63.83
45.15
% Of Sales
-
3.96%
3.47%
3.59%
4.17%
3.46%
2.67%
4.62%
3.51%
3.76%
3.46%
General & Admin Exp.
-
206.67
194.38
172.63
198.71
86.25
66.37
58.16
182.12
159.16
86.87
% Of Sales
-
6.86%
5.82%
4.51%
6.94%
7.21%
4.95%
6.05%
7.14%
9.39%
6.66%
Selling & Distn. Exp.
-
173.21
208.85
161.12
129.57
61.37
66.67
39.94
116.07
88.02
73.40
% Of Sales
-
5.75%
6.26%
4.21%
4.53%
5.13%
4.97%
4.15%
4.55%
5.19%
5.63%
Miscellaneous Exp.
-
99.34
604.48
1,103.88
96.95
29.44
58.33
93.69
50.21
2.76
73.40
% Of Sales
-
3.30%
18.11%
28.85%
3.39%
2.46%
4.35%
9.74%
1.97%
0.16%
0.76%
EBITDA
506.34
450.05
350.74
516.92
380.57
228.85
223.42
100.58
490.68
326.62
186.93
EBITDA Margin
16.59%
14.94%
10.51%
13.51%
13.30%
19.14%
16.66%
10.46%
19.24%
19.26%
14.33%
Other Income
33.59
322.44
805.61
398.08
102.37
38.57
60.23
34.20
31.67
69.70
23.57
Interest
196.56
205.34
196.24
183.10
168.17
47.44
108.88
79.45
194.83
146.65
75.91
Depreciation
171.87
171.85
193.93
198.69
131.25
64.03
56.48
30.86
104.30
63.90
49.19
PBT
167.17
395.30
766.17
533.20
183.50
155.95
118.30
24.48
223.22
185.77
85.41
Tax
22.11
14.49
25.46
51.19
42.45
147.60
40.86
11.15
38.68
45.19
21.90
Tax Rate
13.23%
3.69%
3.52%
10.30%
29.87%
99.35%
44.53%
1.54%
14.18%
24.25%
15.32%
PAT
145.06
372.93
677.27
399.38
113.21
1.57
50.89
712.39
224.48
122.45
109.68
PAT before Minority Interest
142.34
378.19
697.14
445.58
99.68
0.98
50.89
713.44
234.01
141.18
121.04
Minority Interest
-2.72
-5.26
-19.87
-46.20
13.53
0.59
0.00
-1.05
-9.53
-18.73
-11.36
PAT Margin
4.75%
12.38%
20.29%
10.44%
3.96%
0.13%
3.80%
74.07%
8.80%
7.22%
8.41%
PAT Growth
75.68%
-44.94%
69.58%
252.78%
7,110.83%
-96.91%
-92.86%
217.35%
83.32%
11.64%
 
Unadjusted EPS
37.15
36.25
73.81
44.73
13.14
141.85
298.56
121.47
38.65
26.11
26.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Shareholder's Funds
2,648.70
2,454.56
2,748.82
2,657.87
1,144.92
1,006.83
2,026.24
1,371.48
1,282.78
831.07
Share Capital
89.55
89.50
89.42
89.35
59.62
59.57
58.80
58.38
57.74
89.38
Total Reserves
2,551.59
2,356.00
2,650.55
2,562.75
1,084.50
947.06
1,963.94
1,310.34
1,222.95
724.09
Non-Current Liabilities
2,348.41
1,908.40
2,048.67
2,760.03
285.79
306.42
900.59
1,132.57
2,012.89
1,459.17
Secured Loans
1,806.50
1,551.09
1,622.87
2,614.88
250.23
274.29
731.15
1,054.31
1,387.39
778.70
Unsecured Loans
0.06
0.23
14.84
12.13
17.16
1.24
0.00
0.00
622.45
678.17
Long Term Provisions
21.52
16.55
25.19
14.45
6.02
16.56
57.25
66.19
0.00
0.00
Current Liabilities
2,703.27
1,899.30
3,103.87
1,891.98
1,019.94
707.37
1,797.29
2,791.73
923.65
684.15
Trade Payables
894.19
712.07
774.09
775.40
234.41
262.31
463.08
585.04
419.85
445.23
Other Current Liabilities
249.77
129.98
819.08
347.93
502.47
127.27
651.65
1,369.80
305.00
64.64
Short Term Borrowings
1,339.02
944.39
1,393.96
700.48
203.03
224.56
599.89
684.65
0.00
0.00
Short Term Provisions
220.29
112.86
116.73
68.19
80.03
93.23
82.66
152.24
198.80
174.28
Total Liabilities
7,853.33
6,416.91
8,034.86
7,360.09
2,469.36
2,096.29
4,795.97
5,342.24
4,491.79
3,232.89
Net Block
3,567.19
2,735.01
2,909.03
2,678.68
701.36
554.53
3,016.72
3,187.64
2,328.27
1,856.59
Gross Block
4,046.10
3,028.73
3,186.12
2,825.43
1,080.55
907.33
3,514.29
3,644.82
2,626.71
2,080.70
Accumulated Depreciation
478.92
293.71
277.09
146.75
379.19
352.80
497.57
457.19
298.44
224.11
Non Current Assets
4,808.08
3,933.32
4,243.05
3,845.20
1,039.91
787.65
3,383.87
3,711.33
2,521.48
2,282.61
Capital Work in Progress
506.00
620.29
780.18
814.88
171.17
99.47
241.44
285.03
191.46
84.66
Non Current Investment
494.34
350.08
315.66
127.19
68.76
41.80
0.00
0.00
1.76
341.36
Long Term Loans & Adv.
223.69
199.64
222.56
201.83
96.72
90.40
118.75
229.99
0.00
0.00
Other Non Current Assets
16.86
28.30
15.62
22.62
1.91
1.45
6.96
8.67
0.00
0.00
Current Assets
3,045.26
2,483.59
3,791.82
3,514.89
1,429.44
1,308.63
1,410.94
1,625.27
1,960.40
950.29
Current Investments
284.75
311.48
1,279.54
1,213.76
561.29
401.24
0.06
0.00
0.00
0.00
Inventories
870.70
552.02
732.80
613.14
207.68
175.99
442.33
479.93
312.00
233.42
Sundry Debtors
987.18
882.18
995.91
1,032.97
389.96
364.00
483.23
538.44
383.78
420.27
Cash & Bank
516.65
303.33
329.48
311.59
146.88
231.15
165.74
259.73
339.45
91.20
Other Current Assets
385.98
138.84
209.70
245.90
123.64
136.26
319.58
347.17
925.17
205.40
Short Term Loans & Adv.
249.11
295.75
244.39
97.54
54.46
79.06
44.38
91.79
850.18
150.94
Net Current Assets
341.99
584.29
687.95
1,622.91
409.50
601.26
-386.35
-1,166.46
1,036.75
266.14
Total Assets
7,853.34
6,416.91
8,034.87
7,360.09
2,469.35
2,096.28
4,795.98
5,342.23
4,491.80
3,232.90

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Cash From Operating Activity
60.05
187.07
288.14
73.25
83.40
-271.68
134.26
457.10
323.93
89.61
PBT
344.37
705.80
497.14
146.44
992.01
2,889.87
949.49
272.69
186.37
142.94
Adjustment
94.59
-274.51
190.92
345.56
-756.73
-2,775.01
-415.93
113.84
178.94
42.76
Changes in Working Capital
-323.14
-190.66
-341.30
-341.71
-95.91
-260.68
-310.56
128.87
-2.09
-82.37
Cash after chg. in Working capital
115.82
240.63
346.76
150.29
139.37
-145.81
223.00
515.40
363.23
103.33
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-55.76
-53.56
-58.62
-77.04
-55.97
-125.87
-88.75
-58.30
-39.29
-13.72
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-148.49
582.59
-686.69
-2,224.83
51.87
4,077.09
806.54
-656.47
-941.00
-147.64
Net Fixed Assets
-80.83
709.54
-236.66
-535.93
-66.57
-119.10
-38.27
-18.46
-42.91
-26.86
Net Investments
-383.09
747.64
-143.27
-1,478.58
78.09
248.81
-508.54
77.70
653.52
-578.46
Others
315.43
-874.59
-306.76
-210.32
40.35
3,947.38
1,353.35
-715.71
-1,551.61
457.68
Cash from Financing Activity
194.27
-1,015.69
338.21
2,943.94
-421.25
-3,318.53
-990.03
89.36
850.09
91.64
Net Cash Inflow / Outflow
105.83
-246.03
-60.33
792.35
-285.98
486.88
-49.23
-110.01
233.03
33.60
Opening Cash & Equivalents
256.16
515.08
1,110.74
298.91
586.00
132.02
211.93
325.17
79.00
45.88
Closing Cash & Equivalent
365.89
256.16
515.08
1,110.74
298.42
586.00
132.02
212.27
325.17
78.78

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Dec 12
Dec 11
Dec 10
Dec 09
Book Value (Rs.)
294.94
273.24
306.41
296.83
191.91
168.99
343.78
233.49
220.07
190.06
ROA
5.24%
9.65%
5.79%
2.03%
0.04%
1.48%
14.07%
4.76%
3.66%
4.36%
ROE
14.84%
26.89%
16.53%
5.25%
0.09%
3.36%
42.16%
17.77%
13.87%
21.45%
ROCE
11.02%
16.09%
10.75%
7.54%
10.92%
7.76%
21.08%
12.82%
11.96%
10.93%
Fixed Asset Turnover
0.83
1.07
1.27
1.47
1.21
0.61
0.27
0.82
0.72
0.80
Receivable days
113.28
102.66
96.77
90.73
114.71
114.80
193.43
65.68
86.42
105.79
Inventory Days
86.21
70.23
64.20
52.34
58.37
83.78
174.61
56.40
58.62
56.75
Payable days
114.64
116.23
117.33
75.51
76.81
112.69
253.28
92.58
119.83
129.46
Cash Conversion Cycle
84.85
56.67
43.64
67.55
96.27
85.89
114.76
29.50
25.22
33.08
Total Debt/Equity
1.22
1.03
1.35
1.34
0.78
0.54
0.79
1.94
1.58
1.79
Interest Cover
2.91
4.68
3.71
1.85
4.13
1.84
10.12
2.40
2.27
2.88

News Update:


  • Strides Pharma Science’s board approves incremental investments in Stelis
    20th Sep 2019, 14:08 PM

    The proposed new investments will be a primary infusion into Stelis which will enable Stelis to achieve its objective of becoming a compelling global player in the biopharmaceutical space

    Read More
  • Strides Pharma Science’s arm acquires USFDA approved manufacturing facility in US
    27th Aug 2019, 09:15 AM

    Micelle’s facility is based in Riviera Beach, Florida and is one of the very few manufacturing facilities in the US

    Read More
  • USFDA completes inspection at Strides Pharma Science’s Chennai facility
    9th Aug 2019, 15:19 PM

    The inspection concluded with “Zero 483 observations"

    Read More
  • Strides Pharma Science’s arm enters into JV with Sun Moral International
    30th Jul 2019, 09:38 AM

    The JV will explore setting up local manufacturing in China in due course

    Read More
  • Strides Pharma Scien - Quarterly Results
    29th Jul 2019, 16:12 PM

    Read More
  • Strides Pharma Science gets EIR for Bangalore facility
    23rd Jul 2019, 15:49 PM

    The facility was inspected by the USFDA in May 2019

    Read More
  • USFDA completes inspection at Strides Pharma Science’s Bangalore facility
    20th Jul 2019, 09:44 AM

    The inspection was completed successfully with a Voluntary Action Indicated classification

    Read More
  • Strides Pharma Science achieves final closure of Arrow transaction
    10th Jul 2019, 09:39 AM

    SPG has received AUD 300 million immediately at closing, while the balance AUD 94 million will be a deferred consideration

    Read More
  • Strides Pharma Science receives warning letter from USFDA for Puducherry facility
    2nd Jul 2019, 11:45 AM

    Puducherry site currently produces 6 ANDAs which will not get impacted by the current development

    Read More
  • Strides Pharma Science receives requisite approvals to exit investment in Arrow
    1st Jul 2019, 09:26 AM

    The company expects the transaction to close on or around July 10, 2019

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.